

Impact of Adjuvant Ocular Interventions on the Quality of Life of Patients with Uveal Melanoma after Proton Beam Therapy

Johannes Gollrad^a Christopher Rabsahl^a Antonia M. Jousen^b
Andrea Stroux^c Volker Budach^a Dirk Böhmer^a Alexander Böker^b

^aDepartment of Radiation Oncology and Radiotherapy, Charité – Universitätsmedizin Berlin, Berlin, Germany;

^bDepartment of Ophthalmology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ^cInstitute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Keywords

Adult ocular oncology · Quality of life · Radiotherapy · Uveal melanoma

Abstract

Introduction: Proton beam therapy is an established primary treatment for patients with nonmetastasized uveal melanoma. Adjuvant local interventions, like intravitreal injections or surgery, were shown to improve long-term eye preservation; however, their impact on the patient's quality of life (QOL) remains unknown. **Methods:** In a post-radiotherapeutic follow-up, we prospectively collected data on QOL, visual acuity, and interventional adjuvant procedures. QOL was measured with QOL-C30 questionnaire and quality of life questionnaire OPT30 at baseline, and at 3 and 12 months after proton therapy. Patients were grouped by the type of adjuvant treatment. The impact on QOL was analyzed by comparing changes in the mean score values and visual acuity for different interventional subgroups, with generalized linear mixed models and Wilcoxon signed-rank tests. **Results:** We received 108 (100%) and 95 (88.0%) questionnaires at 3 and 12 months post-therapy, respectively. Adjuvant interventions included observation ($n = 61, 56.5\%$), intravitreal

injections ($n = 17, 15.7\%$), and an intraocular surgical procedure ($n = 30, 27.8\%$). In the latter group, several QOL items significantly declined after the 3-month adjuvant interval, but they partially recovered at the 12-month follow-up. In all adjuvant-intervention groups, global QOL scores returned to baseline levels at 12 months. **Conclusion:** Posttreatment adjuvant interventions had no long-lasting effects on QOL in patients with uveal melanoma.

© 2021 S. Karger AG, Basel

Introduction

Uveal melanoma is a rare malignancy that affects 5–8 individuals per million annually [1]. It is the most common primary intraocular malignant disease in adults in the Northern Hemisphere. The established eye-conserving treatment options include brachytherapy, with iodine or ruthenium, proton beam radiotherapy, and photon beam radiotherapy. Treatment selection is based on the tumor's location and prominence and on the availability of treatment modalities.

Several primary treatment methods are associated with low local recurrence. Therefore, treatments for pa-

tients with nonmetastasized uveal melanoma aim to provide long-term eye preservation, the best possible visual acuity, and an acceptable quality of life (QOL) [2]. However, eye preservation can often be challenging, particularly for large, highly prominent tumors. Proton therapy (PT) often causes complications, including extensive tumor exudation, retinal detachment, rubeosis iridis, and neovascular glaucoma, which may inevitably lead to secondary enucleation [3–8]. Different adjuvant treatment strategies have been developed to prevent these complications, and at some institutions, adjuvants have become routine in a multimodal approach.

For most patients with small tumors, which were located centrally or in the mid-periphery, observation with regular follow-up visits is a reasonable approach [9]. In other patients, radiation-induced optic nerve and retinal changes can be reduced with repeated intravitreal injections with corticosteroids or an anti-vascular endothelial growth factor agent [10, 11]. Alternatively, for patients with highly prominent tumors, early adjuvant endoresection or endodrainage can limit gross inflammatory reactions after PT and improve eye preservation rates [6, 7, 12]. However, adjuvant interventions may substantially lower the QOL outcome of radiotherapy for uveal melanoma; thus, adjuvants may outweigh the potential benefits of eye preservation. To our knowledge, no previous study has investigated how different adjuvant interventions after PT might affect patient-reported QOL. The present study aimed to determine how adjuvant strategies applied after PT affected QOL in patients treated for uveal melanoma.

Methods

Patients and Study Design

This prospectively designed QOL study included 131 patients with a primary diagnosis of nonmetastasized uveal melanoma and an indication for proton beam therapy, between May 2019 and January 2020. All patients completed 2 questionnaires from the European Organization for Research and Treatment of Cancer (EORTC). These questionnaires surveyed QOL, in general (quality of life questionnaire (QLQ)-C30), and QOL specifically for patients with uveal melanoma (EORTC-OPT30). The study was approved by the Charité Ethics Committee, and it was conducted in accordance with the Declaration of Helsinki.

Questionnaires were completed immediately after PT (baseline, t1), after 3 months (t2), and at 12 months (t3) after completing PT. To determine the potential impact of different adjuvant interventional strategies on the QOL of our patients, we compared results from the EORTC QLQ-C30 and EORTC-OPT30 questionnaires and from visual acuity tests performed at t1 to the same results collected at t2 and t3. To compare the effects of different

adjuvant interventions, we analyzed the following groups: observation group: patients who received no adjuvant treatment; injection group: patients who received an adjuvant intravitreal injection and laser treatment; and surgery group: patients who underwent an adjuvant vitrectomy with endoresection or endodrainage.

Measures

The EORTC QLQ-C30 (version 3.0) is a validated questionnaire and is frequently used in the context of cancer care [13]. It comprises 30 questions and 6 functional scales, covering a wide range of physical and mental symptoms. The EORTC QLQ-OPT30 is an ophthalmologic extension module for the QLQ-C30, designed to assess QOL in patients with ocular tumors. It focuses on visual and ocular symptoms [14]. Both EORTC questionnaires were evaluated with standardized procedures, according to the respective EORTC scoring manuals. Visual acuity was assessed as the best corrected visual acuity. Results are expressed in decimal notation.

Procedures

Proton Beam Therapy

For treatment planning, we performed fundoscopy, ultrasound, CT, and, in some cases, MRI. These data were integrated into a three-dimensional eye model.

In preparation for proton beam therapy, 4 tantalum clips were sutured onto the sclera to ensure an accurate eye position and gaze angle during the irradiation procedure. Immediately before each proton beam session, the correct eye position, according to the treatment plan, was verified with 2-plane X-ray imaging. During treatment, patients were immobilized with a thermoplastic mask and an integrated bite block.

PT was delivered on 4 consecutive days, at fractions of 15 cobalt gray equivalent per day, with a 40- to 60-s beam-on time. Detailed procedures and beam specifications were described previously [15, 16].

Intravitreal Injection and Laser Treatment

Intravitreal injections of corticosteroid (triamcinolone) or anti-vascular endothelial growth factor antibody (bevacizumab) were administered for treating minor subretinal fluid exudations from the tumor. Injections were performed with a standardized procedure, according to national guidelines. Briefly, either 0.1 mL triamcinolone (10 mg/mL) or 0.05 mL bevacizumab (5 mg/0.2 mL) was injected with a 30-g syringe into the vitreous body, at 3.5 mm from the limbus. When residual fluid persisted, the injection could be repeated after an interval of at least 4 weeks.

When intravitreal injections did not suffice, transpupillary thermotherapy was applied to the surface of the tumor to reduce tumor exudation. Briefly, after applying analgesia and local anesthesia, thermotherapy was performed at 810 nm with a diode laser mounted on a slit-lamp biomicroscope. Deeper penetration was achieved with a long exposure time and lower energy settings. The entire tumor surface was covered in an overlapping manner. To treat postradiation peripheral retinal ischemia, we applied retinal laser scatter treatment to the ischemic areas.

Surgical Intervention with Vitrectomy and Endoresection or Endodrainage

Patients with large, highly prominent tumors (i.e., height >6 mm) underwent preplanned endoresections as part of a multi-

Table 1. Patient and tumor characteristics for patients treated for uveal melanoma, stratified by adjuvant treatment strategy

Characteristics	All patients		Adjuvant treatment strategy						p value
			no adjuvant treatment (OS)		intravitreal injection (IN)		endoresection (SU)		
Patients, <i>n</i>	108		61	56.5%	17	15.7%	30	27.8%	
Male	52	48.1%	28	45.9%	8	47.1%	16	53.3%	0.797*
Female	56	51.9%	33	54.1%	9	52.9%	14	46.7%	
Mean age, years	59.8	±13.7	59.8	±14.1	58.5	±13.6	60.5	±13.3	0.919
AJCC tumor stages									
T1a/c	42	38.9%	41	67.2%	1	5.9%	0	0.0%	
T2a/b	37	34.3%	18	29.5%	9	52.9%	10	33.3%	<0.001*
T3a/b	23	21.3%	2	3.3%	6	35.3%	15	50.0%	
T4a/b	6	5.6%	0	0.0%	1	5.9%	5	16.7%	
Tumor characteristics									
Tumor prominence, mm	4.4	±3.0	2.6	±1.2	4.6	±2.2	8.1	±2.8	<0.001
Tumor base diameter, mm	14.8	±3.8	12.9	±3	16.7	±4.1	17.7	±2.7	<0.001
Tumor volume, mm ³	458	±445	196	±156	608	±491	904	±430	<0.001
Distance between tumor and fovea, mm	1.9	±3.1	1.6	±3.1	1.5	±1.8	3	±3.4	0.034
Distance between tumor and optic disc, mm	2.6	±3.3	2.3	±2.9	1.3	±1.3	4.1	±4.4	0.090

Values are the mean and standard deviation (±SD). AJCC, American Joint Cancer Committee. * Significant differences between independent subgroups based on the Kruskal-Wallis test ($p < 0.05$). or χ^2 test ($p < 0.05$), as appropriate.

modal treatment. Smaller tumors with excessive exudation received vitrectomy, followed by endodrainage of the subretinal fluid.

Prior to an endoresection, the crystalline lens was removed by phacoemulsification, and the posterior chamber lens was implanted to facilitate the intraocular procedure. After a pars plana vitrectomy, the irradiated tumor tissue was removed with a vitrectome. During resection, the systemic blood pressure was lowered to a mean arterial pressure of 60–65 mm Hg, and the intraocular pressure was elevated to reduce the risk of bleeding complications.

Prior to an endodrainage, a pars plana vitrectomy was performed. Then, a retinal tear was surgically performed in the periphery of the retina, within the 10–2 clock-hour section of the eye. Next, a perfluorocarbon liquid was injected into the vitreous cavity to drive out any fluid from the subretinal space. Finally, the perfluorocarbon liquid was replaced with silicon oil, which was removed after 6 months.

Statistics

Statistical evaluations were performed with R (version 4.1.0). To examine the effects of adjuvant treatments over time, we constructed generalized linear mixed models with a baseline adjustment. Exploratory interaction analyses included a post hoc comparison of mean questionnaire scores recorded at different time points in all subgroups; scores were compared with a paired Wilcoxon signed-rank test and the Bonferroni correction for multiple testing. Changes with p values ≤ 0.05 were considered significant. Differences between independent subgroups regarding patient and tumor characteristics were analyzed with Kruskal-Wallis and Mann-Whitney U tests, with a significance threshold of $p \leq 0.05$.

Results

Study Sample

Of 131 prospectively included participants, 120 (91.6%) returned the questionnaires immediately after proton beam therapy (t1). Three months after proton beam therapy (t2), 108 (82.4%, 50 female) patients completed the follow-up assessment and therefore were included in the analyses. Of these, 95 (88.0%) patients completed the questionnaires at 12 months after PT (t3). During the 12-month follow-up, 1 patient was excluded for an unplanned enucleation; thus, the eye preservation rate was 99.1%. Three patients (2.8%) developed distant metastasis, and no patient experienced local tumor recurrence. The mean time intervals between the end of radiotherapy and questionnaire completion were 98.8 (SD 7.0) days (t2) and 383.4 (SD 12.3) days (t3).

During t2, 61 (56.5%) patients were observed, 17 (15.7%) patients received injections, and 30 (27.8%) patients received intraocular surgery. Overall, 87.0% of the actual adjuvant treatments adhered to the pretreatment tumor board protocol. Adherence rates were 95.1% in the observation group, 64.7% in the injection group, and 83.3% in the surgery group.

Five patients in the injection group received additional transpupillary thermotherapy due to persistent or recurring subretinal fluid. The average time from proton

beam therapy to thermotherapy was 6 months. In 1 patient, retinal laser treatment was performed 11 months after proton beam therapy due to radiation-induced retinopathy.

In the surgery group, 23 patients received a pars plana vitrectomy with endoresection of the tumor. Additionally, 7 patients underwent a pars plana vitrectomy with endodrainage of the subretinal fluid.

Among the 108 included patients, the mean age was 59.2 (SD 13.7) years. The subgroups were equivalent with respect to age and sex. Significant differences among subgroups included tumor stage ($p \leq 0.001$), tumor volume ($p \leq 0.001$), maximal basal diameter ($p \leq 0.001$), tumor thickness ($p \leq 0.001$), and distance between the tumor and fovea ($p \leq 0.034$; Table 1).

Quality of Life

EORTC QLQ-C30

At t2 and t3, we observed a trend of gradual improvement in global QOL (Table 2) in the observation and injection groups, although the changes did not reach significance. In contrast, in the surgery group, the global QOL declined insignificantly during t1-t2, but then, it significantly improved at t3 (t1 QOL = 68.52 vs. t3 QOL = 72.57, $p = 0.018$).

In the surgery group, the mean scores for all the individual QLQ-C30 functional scales declined during the t1-t2 period. In this group, “physical functioning” ($p = 0.020$) and “role functioning” ($p = 0.002$) declined significantly. After these marked declines, neither score recovered fully, although “role functioning” partially recovered at the 12-month follow-up (t1 = 80.25, t2 = 67.82, t3 = 71.53). These declines reflected the substantial impact of intraocular surgery on everyday activities. In the observation and injection groups, “emotional functioning” improved at t2. This change was significant in the observation group ($p = 0.05$), and it continued to improve at t3. In contrast, the surgery group showed no improvement in “emotional functioning” at t2 or t3.

EORTC QLQ-OPT30

In the observation subgroup, we observed a significant improvement in “ocular irritation” at t2 ($p \leq 0.001$, Table 3). In contrast, in the other 2 groups, patients reported only minor, nonsignificant changes in symptoms related to “ocular irritation.” However, at t2, the surgery group reported significant increases in symptoms for several QLQ-OPT30 items, including “problems with exterior aspect” ($p = 0.041$), “functional problems with visual impairment” ($p = 0.002$), “functional problems with the

treated eye” ($p = 0.005$), and “problems with driving” ($p \leq 0.001$). In contrast, at t2, the injection and observation groups showed no change or improvements in most QLQ-OPT30 items, and the only significant change was in “ocular irritation” in the observation group.

At t3, the surgery group showed improvements in all QLQ-OPT30 items, with significant recoveries noted in “functional problems with visual impairment” ($p = 0.009$), “problems with driving” ($p = 0.009$), and “headache” ($p = 0.012$). At the same time, the observation and injection groups showed a trend of worsening ocular symptoms. Only the observation group showed significant deteriorations at t3 in “ocular irritation” ($p = 0.003$) and “functional problems with visual impairment” ($p = 0.006$).

Correlations between the QOL Outcome and Baseline (t1) Tumor Characteristics

Immediately after PT (t1), no tumor characteristics were significantly correlated to the QOL items on the QLQ-C30 except one: a short distance between the tumor and fovea was correlated to the global QOL ($p = 0.013$) and “emotional functioning” ($p = 0.036$). However, the baseline QLQ-OPT30 showed significant correlations between tumor prominence and “visual impairment” ($p = 0.04$), “functional problems with visual impairment” ($p = 0.021$), and “functional problems with the treated eye” ($p = 0.013$) (Fig. 1). In addition, tumor volume was significantly correlated with “functional problems with the treated eye” ($p = 0.013$). No tumor characteristics were significantly correlated with “ocular irritation,” “headache,” “problems with reading,” “problems with exterior aspect,” or “problems with driving.”

Visual Acuity

In the observation group, the median visual acuity declined from 0.63 (SD 0.38) at baseline to 0.50 (SD 0.34) at t2 ($p = 0.020$) and then recovered to 0.63 (SD 0.35) at t3. In the surgery group, visual acuity significantly deteriorated, from 0.4 at baseline (SD 0.34) to 0.08 (SD 0.15) at t2 ($p \leq 0.001$), and then, it subsequently improved to 0.20 (SD 0.16) at t3 ($p = 0.003$). In the injection group, visual acuity did not significantly change over time (Fig. 2).

Visual acuity was significantly correlated with worsening QOL in several functional subscales. At t2, worse visual acuity was associated with declines in “role functioning” ($p = 0.009$), “visual impairment” ($p \leq 0.001$), “functional problems with visual impairment” ($p \leq 0.001$), “functional problems with the treated eye” ($p = 0.005$), and “problems with driving” ($p = 0.004$).

Table 2. Results from the EORTC QLQ evaluated over time in different adjuvant treatment groups

EORTC QLQ-C30	Type of adjuvant treatment						endoresection/drainage (SU)											
	no adjuvant treatment (OS)			intravitreal injection (IN)			mean			±SD			t1:t2			t2:t3		
	mean	±SD	t1:t2	t2:t3	mean	±SD	t1:t2	t2:t3	mean	±SD	t1:t2	t2:t3	mean	±SD	t1:t2	t2:t3		
Global health score																		
t1	68.27	20.26	$p = 0.319$		54.90	25.01	$p = 0.061$		68.52	17.35	$p = 0.229$		64.37	17.66		$p = 0.018$		
t2	71.25	18.44		$p = 0.495$	67.22	16.80		$p = 0.665$	64.37	17.66		$p = 0.665$	72.57	19.58				
t3	73.21	19.12			67.86	21.40			72.57	19.58								
Functional scales																		
Physical functioning																		
t1	88.05	18.20	$p = 0.049$		84.71	22.33	$p = 0.526$		91.67	10.28	$p = 0.020$		86.89	13.62		$p = 0.879$		
t2	85.39	21.45		$p = 0.041$	89.17	18.68		$p = 0.312$	86.89	13.62		$p = 0.312$	85.56	19.23				
t3	88.81	17.76			86.67	26.41			85.56	19.23								
Role functioning																		
t1	74.71	27.79	$p = 0.954$		68.63	33.27	$p = 0.748$		80.25	24.04	$p = 0.002$		67.82	25.95		$p = 0.183$		
t2	74.32	26.45		$p = 0.649$	73.96	20.16		$p = 0.277$	67.82	25.95		$p = 0.277$	71.53	25.29				
t3	76.19	26.56			65.48	25.71			71.53	25.29								
Emotional functioning																		
t1	71.05	22.55	$p = 0.050$		63.73	25.51	$p = 0.365$		70.99	24.61	$p = 0.314$		69.35	18.29		$p = 0.689$		
t2	75.91	22.85		$p = 0.730$	70.56	24.57		$p = 0.477$	69.35	18.29		$p = 0.477$	67.59	22.91				
t3	78.17	21.41			70.63	25.73			67.59	22.91								
Cognitive functioning																		
t1	86.84	19.60	$p = 0.403$		77.45	29.43	$p = 0.490$		83.95	17.59	$p = 0.210$		80.00	22.49		$p = 0.202$		
t2	83.06	20.30		$p = 0.214$	77.78	22.42		$p = 0.645$	80.00	22.49		$p = 0.645$	77.78	17.49				
t3	82.14	20.31			80.95	15.82			77.78	17.49								
Social functioning																		
t1	81.58	21.75	$p = 0.062$		74.51	29.53	$p = 0.591$		80.86	24.33	$p = 0.146$		77.01	20.61		$p = 0.710$		
t2	86.67	22.51		$p = 0.046$	80.00	24.56		$p = 0.833$	77.01	20.61		$p = 0.833$	77.78	25.85				
t3	86.31	22.04			80.95	24.33			77.78	25.85								
Single item																		
Pain																		
t1	15.23	24.22	$p = 0.229$		19.61	32.93	$p = 0.450$		9.87	15.51	$p = 0.063$		16.11	18.82		$p = 0.289$		
t2	11.20	21.88		$p < 0.001$	9.38	22.75		$p = 0.045$	16.11	18.82		$p = 0.045$	17.86	24.31				
t3	18.97	25.59			16.96	24.51			17.86	24.31								

Values are the mean scores and standard deviations (SD). t1, immediately after PT; t2, 3 months after PT; t3, 12 months after PT. Bold font: p value ≤ 0.05 indicates a significant change between the indicated assessment points, according to the paired Wilcoxon signed-rank test. QLQ, quality of life questionnaire; EORTC, European Organization for Research and Treatment of Cancer; PT, proton therapy.

Table 3. Results from the EORTC QLQ, ophthalmologic module (OPT), evaluated over time in different adjuvant treatment groups

EORTC QLQ-OPT30	Type of adjuvant treatment						endoresection/drainage (SU)					
	no adjuvant treatment (OS)			intravitreal injection (IN)			endoresection/drainage (SU)			endoresection/drainage (SU)		
	mean	±SD	t1:t2	t2:t3	mean	±SD	t1:t2	t2:t3	mean	±SD	t1:t2	t2:t3
Functional scales time												
Ocular irritation*												
t1	26.59	20.81	p < 0.001		24.05	20.43	p = 0.807		28.72	16.89	p = 0.389	
t2	19.34	17.75		p < 0.003	21.18	20.31		p = 0.432	30.37	19.17		p = 0.201
t3	24.11	21.25			20.32	19.38			26.62	13.90		
Visual impairment												
t1	16.27	22.32	p = 0.741		28.76	29.15	p = 0.788		25.10	25.71	p = 0.053	
t2	16.67	20.71		p = 0.701	24.31	16.34		p = 0.075	34.44	26.96		p = 0.079
t3	17.58	23.20			35.04	23.94			29.71	22.45		
Worry about recurrence												
t1	40.77	29.72	p = 0.885		61.76	30.05	p = 0.629		50.93	30.69	p = 0.585	
t2	40.35	28.01		p = 0.843	55.56	28.60		p = 0.506	53.06	27.81		p = 0.867
t3	38.39	27.19			51.79	30.52			50.35	22.98		
Problems with exterior aspect*												
t1	29.41	28.40	p = 0.091		29.41	30.35	p = 0.246		17.28	23.33	p = 0.041	
t2	21.11	25.83		p = 0.121	16.67	23.57		p = 0.528	26.11	27.57		p = 0.411
t3	25.60	25.42			11.90	17.82			20.83	27.47		
Functional problems visual impairment*												
t1	19.39	22.51	p = 0.481		31.05	28.94	p = 0.932		24.31	22.66	p = 0.002	
t2	19.76	20.60		p = 0.006	29.90	19.13		p = 0.272	36.48	24.49		p = 0.009
t3	22.54	21.58			26.19	20.26			29.40	22.07		
Functional problems with treated eye**												
t1	27.67	23.08	p = 1.000		39.22	24.48	p = 0.615		31.55	20.82	p = 0.005	
t2	27.93	19.72		p = 0.241	34.90	19.65		p = 0.263	42.41	25.49		p = 0.429
t3	31.24	32.10			39.40	26.92			37.22	22.75		
Problems with driving*												
t1	27.33	30.45	p = 0.473		34.44	27.07	p = 0.454		21.79	27.39	p < 0.001	
t2	28.95	27.19		p = 0.063	28.13	21.70		p = 0.345	53.45	34.90		p = 0.009
t3	32.08	29.02			30.95	26.03			35.51	29.43		
Single items												
Headache*												
t1	16.07	24.61	p = 0.374		21.57	33.21	p = 0.114		16.05	28.30	p = 0.037	
t2	18.03	29.55		p = 0.818	10.42	15.96		p = 0.336	31.03	32.04		p = 0.012
t3	18.45	26.91			11.90	16.57			15.28	25.97		
Problems with reading												
t1	36.31	29.32	p = 0.148		56.86	30.65	p = 1.000		35.71	23.88	p = 0.148	
t2	39.89	30.32		p = 0.897	56.86	25.72		p = 0.213	40.23	27.28		p = 0.891
t3	41.67	34.38			61.90	22.81			43.06	25.02		

Values are the mean scores and standard deviations (SD). t1, immediately after PT; t2, 3 months after PT; t3, 12 months after PT. Bold font indicates a significant change between the indicated assessment points (p value ≤ 0.05), according to the paired Wilcoxon signed-rank test. QLQ, quality of life questionnaire; EORTC, European Organization for Research and Treatment of Cancer; PT, proton therapy. * p ≤ 0.05 and ** p ≤ 0.1 indicate a significant interaction between the treatment type and time, according to a mixed generalized linear model.




Fig. 1. Mean score values for the multi-item scales and single items of the European Organization for Research and Treatment of Cancer Quality of Life ophthalmologic cancer module (EORTC QLQ-OPT30). Bars show values recorded directly after PT (dark blue), 3 months after PT (medium blue), and 12 months after PT (light blue), grouped by the adjuvant treatment type. * $p \leq 0.05$, ** $p \leq$

0.01, *** $p \leq 0.001$, and **** $p \leq 0.0001$ indicate significant changes between assessments, detected with the paired Wilcoxon signed-rank test. ns, not significant; PT, proton therapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ, quality of life questionnaire.

Discussion

The present study revealed that all patients had stable global health scores in the short-term after proton beam therapy, regardless of the adjuvant treatment strategy. A

direct comparison of the QOL outcome between the subgroups was not feasible because the baseline QOL results clearly reflected a selection bias for adjuvant treatments. Indeed, the adjuvant treatment strategies proposed by the local tumor board were based on significantly different




Fig. 2. Visual acuity in patients with uveal melanoma treated with PT, with or without a subsequent adjuvant intervention. Bars show values recorded directly after PT (dark blue), 3 months after PT (medium blue), and 12 months after PT (light blue), grouped by the adjuvant treatment type. A mixed generalized linear model

showed a significant interaction between the treatment type and time ($p = 0.018$). $*p \leq 0.05$, $**p \leq 0.01$, $***p \leq 0.001$, and $****p \leq 0.0001$ indicate significant changes between assessments, detected with the paired Wilcoxon signed-rank test. ns, not significant; PT, proton therapy.

tumor characteristics and tumor stages among the 3 subgroups. Therefore, we analyzed longitudinal changes in QOL for each subgroup by comparing QOL questionnaire results collected immediately after the radiotherapy to those collected at 3 and 12 months.

We observed a nonsignificant trend in improved global QOL at t2 in the observation group, which was not observed in the surgery subgroup. This trend could be essentially explained by recoveries in the emotional ($p = 0.05$) and social functioning ($p = 0.062$) subscales after the initial treatment. At the same time, physical functioning declined in the observation group ($p = 0.049$), which could be explained by the deterioration in visual acuity. These results were consistent with observations in several previous studies on the general QOL of patients with uveal melanoma after various primary treatments [17–20]. For example, Suchocka-Capugno et al. [19] and Brandberg et al. [17] found that plaque therapy or enucleation had an overall low impact on the general QOL at 1 year after treatment, and anxiety symptoms declined within 2 months after treatment. However, our results contrasted with those of Suchocka-Capugno et al. [19],

who described a decline in “social functioning” during a 12-month follow-up.

Our findings on social functioning in the observation group may reflect a faster reintegration into their social life due to less hospitalization and better outcomes in “problems with exterior aspect” ($p = 0.091$) and “ocular irritation” ($p \leq 0.001$). Interestingly, “worry about recurrence” did not significantly improve during the follow-up, regardless of the adjuvant treatment. In contrast, previous studies consistently reported improvements in anxiety issues for patients with uveal melanoma within the 1st 2 years after a primary treatment, compared to pretreatment assessments [19, 21, 22]. However, another study found that anxiety receded, to a large extent, immediately after PT and remained relatively stable thereafter [23].

We observed a similar trend of improved global QOL in the injection subgroup. However, we did not detect any significant changes in the EORTC QLQ-C30 subscales, in the QLQ-OPT30 subscales or in visual acuity.

As expected, the surgery group showed the worst QOL outcome, in terms of “physical functioning” ($p < 0.001$)

and “role functioning” ($p < 0.001$) at t2 compared to t1. In previous studies without pretreatment assessments, these early changes were attributed to the more advanced tumor stages in this group, or they were considered early radiation side effects. Indeed, our surgery group showed a significant recovery of global QOL ($p = 0.018$) at t3, which supported the notion that major parts of the early transient QOL decline could be related to the type of adjuvant treatment.

In the surgery subgroup, the most significant deteriorations at t2 reflected the functional aspects of ocular impairment, like “functional problems with visual impairment” ($p = 0.002$), “functional problems with the treated eye” ($p = 0.005$), and “problems with driving” ($p < 0.001$). Importantly, all these ocular deteriorations recovered at t3 in the surgery subgroup. Significant recoveries were observed in “functional problems with visual impairment” ($p = 0.002$) and “problems with driving” ($p = 0.009$). These characteristic changes were clearly related to the adjuvant treatment period, and they were only observed in the surgery group. Therefore, these changes most likely reflected the impact of the surgical interventions on QOL issues and visual acuity.

Previous studies reported improved eye preservation rates in patients with large tumors after an adjuvant endoresection compared to an observational control group [7]. However, it remains unclear whether the QOL in those patients was related to successful eye preservation alone or whether the QOL might also have been influenced by additional morbidities associated with the adjuvant surgical treatment. Several authors reported that QOL was similar between patients who underwent enucleation and patients who underwent eye-preserving therapy [17, 18, 21, 24–26]. In a large study with 1,596 patients, Damato et al. found that QOL outcomes were worse after primary enucleation than after radiotherapy [26]. A more detailed look at those data revealed that patients who underwent enucleation were older and had more comorbidities than patients who received radiotherapy; thus, these differences might have influenced the results.

Study Strengths and Limitations

The present study strengths were the prospectively collected data and the longitudinal design, which allowed comparisons between subgroups with very different tumor characteristics. Another strength was the high adherence to adjuvant strategies planned by the pretreatment tumor board protocol. This adherence minimized confounding factors related to ad hoc inter-

ventions that are occasionally performed during the adjuvant period.

Our study also had some limitations. The overall follow-up time was relatively short; thus, it mainly reflected transient ocular symptoms associated with adjuvant interventions. However, long-term studies run the risk that these side effects might be confounded with evolving radiation-induced late toxicity. Consequently, our findings may be limited in portraying the long-term impact of adjuvant interventions on the QOL of patients treated for uveal melanoma. In addition, our adjuvant treatment subgroups varied considerably in size. In particular, the injection subgroup only included 17 patients; therefore, the results for that subgroup should be interpreted with caution.

Conclusion

The present study showed that, after 12 months, the global QOL may be unaffected, regardless of the adjuvant therapy applied. Nevertheless, patients and treating physicians should be aware that adjuvant surgical interventions may compromise the ophthalmological QOL of the patient. Our findings may inform patients and treating physicians in making individually tailored decisions, when selecting the appropriate primary treatment and consecutive interventional strategies.

Statement of Ethics

This study protocol was reviewed and approved by the Charité Ethics Committee, approval number EA4-031-19. Written informed consent was obtained from all participants to participate in the study.

Conflict of Interest Statement

Johannes Gollrad was involved in scientific presentations at symposia for Varian Medical Systems International AG in 2019 and 2020, with no conflict of interest to the actual manuscript. Christopher Rabsahl, Andrea Stroux, and Alexander Böker have no conflict of interest to declare. Antonia M. Jousen, Volker Budach, and Dirk Böhmer have no conflict of interest to declare related to the manuscript.

Funding Sources

There was no funding for this study.

Author Contributions

Johannes Gollrad made substantial contributions to the conception and design of the work; the acquisition, analysis, and interpretation of data for the work; drafting the work; and revising it critically for important intellectual content. Christopher Rabsahl made substantial contributions to the acquisition and analysis of data for the work and drafting the work. Antonia M. Jousen made substantial contributions to the interpretation of data for the work and revising it critically for important intellectual content. Andrea Stroux made substantial contributions to analysis and interpretation of data for the work and revising it critically for important intellectual content. Volker Budach made substantial contributions to the conception of the work and revising it critically for

important intellectual content. Dirk Böhmer made substantial contributions to the conception of the work and revising it critically for important intellectual content. Alexander Böker made substantial contributions to the design of the work, the analysis and interpretation of data for the work, drafting the work, and revising it critically for important intellectual content.

Data Availability Statement

The data that support the findings of this study are not publicly available due to concerns related that could compromise the privacy of research participants but are available from the corresponding author A.B. upon reasonable request.

References

- 1 Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. *Ophthalmology*. 2007 Dec;114(12):2309–15.
- 2 Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. *Clin Oncol*. 2016 Aug;28(8):e17–27.
- 3 Damato B, Groenewald C, McGalliard J, Wong D. Endoresection of choroidal melanoma. *Br J Ophthalmol*. 1998 Mar;82(3):213–8.
- 4 Bechrakis NE, Petousis V, Krause L, Wachtlin J, Willerding G, Foerster MH. [Surgical treatment modalities in uveal melanomas]. *Klin Monbl Augenheilkd*. 2009 Nov;226(11):921–6.
- 5 Ly LV, Bronkhorst IH, van Beelen E, Vrolijk J, Taylor AW, Versluis M, et al. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. *Invest Ophthalmol Vis Sci*. 2010 Nov;51(11):5445–51.
- 6 Seibel I, Cordini D, Willerding G, Riechardt AI, Jousen AM. Endodrainage, tumor photocoagulation, and silicone oil tamponade for primary exudative retinal detachment due to choroidal melanoma persisting after proton beam therapy. *Ocul Oncol Pathol*. 2014 Oct;1(1):24–33.
- 7 Seibel I, Riechardt AI, Heufelder J, Cordini D, Jousen AM. Adjuvant ab interno tumor treatment after proton beam irradiation. *Am J Ophthalmol*. 2017 Jun;178:94–100.
- 8 Boker A, Pilger D, Cordini D, Seibel I, Riechardt AI, Jousen AM, et al. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma. *Graefes Arch Clin Exp Ophthalmol*. 2018 Sep;256(9):1767–75.
- 9 Eckstein D, Riechardt AI, Heufelder J, Zeitz O, Boker A, Brockmann C, et al. Radiation-induced optic neuropathy: observation versus intravitreal treatment: can visual acuity be maintained by intravitreal treatment? *Am J Ophthalmol*. 2019 Dec;208:289–94.
- 10 Chang M, Dalvin LA, Mazloumi M, Martin A, Yaghy A, Yang X, et al. Prophylactic intravitreal bevacizumab after plaque radiotherapy for uveal melanoma: analysis of visual acuity, tumor response, and radiation complications in 1131 eyes based on patient age. *Asia Pac J Ophthalmol*. 2020 Jan-Feb;9(1):29–38.
- 11 Seibel I, Vollhardt D, Riechardt AI, Rehak M, Schmied S, Schiller P, et al. Influence of ranibizumab versus laser photocoagulation on radiation retinopathy (RadiRet): a prospective randomized controlled trial. *Graefes Arch Clin Exp Ophthalmol*. 2020 Apr;258(4):869–78.
- 12 Bechrakis NE, Höcht S, Martus P, Kreusel KM, Heese J, Foerster MH. [Endoresection following proton beam irradiation of large uveal melanomas]. *Ophthalmologe*. 2004 Apr;101(4):370–6.
- 13 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993 Mar 3;85(5):365–76.
- 14 Brandberg Y, Damato B, Kivela T, Kock E, Seregard S, Force EOOT, et al. The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (Phase I-III). *Eye*. 2004 Mar;18(3):283–9.
- 15 Hocht S, Bechrakis NE, Nausner M, Kreusel KM, Kluge H, Heese J, et al. Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. *Strahlenther Onkol*. 2004 Jul;180(7):419–24.
- 16 Marnitz S, Cordini D, Bendl R, Lemke AJ, Heufelder J, Simiantonakis I, et al. Proton therapy of uveal melanomas: intercomparison of MRI-based and conventional treatment planning. *Strahlenther Onkol*. 2006 Jul;182(7):395–9.
- 17 Brandberg Y, Kock E, Oskar K, af Trampe E, Seregard S. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. *Eye*. 2000 Dec;14(Pt 6):839–46.
- 18 Melia M, Moy CS, Reynolds SM, Hayman JA, Murray TG, Hovland KR, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. *Arch Ophthalmol*. 2006 Feb;124(2):226–38.
- 19 Suchocka-Capitano A, Bredart A, Dolbeault S, Rouic LL, Levy-Gabriel C, Desjardins L, et al. [Quality of life and psychological state in patients with choroidal melanoma: longitudinal study]. *Bull Cancer*. 2011 Feb;98(2):97–107.
- 20 van Beek JGM, Buitendijk GHS, Timman R, Muller K, Luyten GPM, Paridaens D, et al. Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients. *Acta Ophthalmol*. 2018 Dec;96(8):841–8.
- 21 Hope-Stone L, Brown SL, Heimann H, Damato B. Comparison between patient-reported outcomes after enucleation and proton beam radiotherapy for uveal melanomas: a 2-year cohort study. *Eye*. 2019 Sep;33(9):1478–84.
- 22 Scannell O, O'Neill V, Dunne M, Baily C, Salih A, Cunningham M, et al. Quality of life in uveal melanoma patients in Ireland: a single-centre survey. *Ocul Oncol Pathol*. 2020 Mar;6(2):99–106.
- 23 Gollrad J, Rabsahl C, Riechardt AI, Heufelder J, Stroux A, Goerling U, et al. Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma. *Radiat Oncol*. 2021 Sep 8;16(1):174.
- 24 Chabert S, Velikay-Parel M, Zehetmayer M. Influence of uveal melanoma therapy on patients' quality of life: a psychological study. *Acta Ophthalmol Scand*. 2004 Feb;82(1):25–31.
- 25 Amaro TA, Yazigi L, Erwenne C. Depression and quality of life during treatment of ocular bulb removal in individuals with uveal melanoma. *Eur J Cancer Care*. 2010 Jul;19(4):476–81.
- 26 Damato B, Hope-Stone L, Cooper B, Brown SL, Salmon P, Heimann H, et al. Patient-reported outcomes and quality of life after treatment of choroidal melanoma: a comparison of enucleation versus radiotherapy in 1596 patients. *Am J Ophthalmol*. 2018 Sep;193:230–51.